about
Isolation and characterization of the circulating form of human endostatin.The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formationUrokinase receptor (CD87) clustering in detergent-insoluble adhesion patches leads to cell adhesion independently of integrins.A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells.The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: implications for cardiovascular function.Urokinase receptor: a molecular organizer in cellular communication.Components of the plasminogen activation system promote engraftment of porous polyethylene biomaterial via common and distinct effects.Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and MortalityFactor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation.Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo.Factor VII activating protease (FSAP) influences vascular remodeling in the mouse hind limb ischemia model.Factor VII activating protease. Single nucleotide polymorphisms light the way.At the interface of fibrinolysis and inflammation: the role of urokinase-type plasminogen activator in the leukocyte extravasation cascade.Factor VII activating protease (FSAP): a novel protective factor in liver fibrosis.A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7.Transforming Growth Factor-β (TGF-β) Inhibits the Expression of Factor VII-activating Protease (FSAP) in Hepatocytes.The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.The factor VII-activating protease (FSAP) enhances the activity of bone morphogenetic protein-2 (BMP-2).Structure-function analysis of factor VII activating protease (FSAP): sequence determinants for heparin binding and cellular functions.Factor seven ativating potease (FSAP) levels during normal pregnancy and in women using oral contraceptives.Promotion of leukocyte adhesion by a novel interaction between vitronectin and the beta2 integrin Mac-1 (alphaMbeta2, CD11b/CD18).Variability in the expression of urokinase receptor (CD87) mutants on cells: relevance to cell adhesion.Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes.Molecular interactions and functional interference between vitronectin and transforming growth factor-beta.Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen.Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins.Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.Ferric chloride-induced arterial thrombosis in mice.Modulation of endothelin receptor expression in human vascular smooth muscle cells by interleukin-1 beta.The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density.Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice.Pituitary adenylate cyclase-activating polypeptide releases 7B2, adrenocorticotrophin, growth hormone and prolactin from the mouse and rat clonal pituitary cell lines AtT-20 and GH3.Peptide contents of neuropeptide Y, vasoactive intestinal polypeptide, and beta-calcitonin gene-related peptide and their messenger ribonucleic acids after dexamethasone treatment in the isolated rat islets of Langerhans.Integrin chatter and vascular function in diabetic retinopathy.Nucleic acids potentiate Factor VII-activating protease (FSAP)-mediated cleavage of platelet-derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation.A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding.Inhibition of PDGF-BB by Factor VII-activating protease (FSAP) is neutralized by protease nexin-1, and the FSAP-inhibitor complexes are internalized via LRP.Release of substance P from rat hypothalamus and pituitary by endothelin.Production of endothelin by vascular smooth muscle cells.
P50
Q32127286-6775A7C5-FB3F-401A-B9A1-28FE3C9910FFQ33265417-88EFED80-658C-4F59-AB50-2BFCEFF9C29FQ33303706-E62470A2-87FB-4CC6-BD4B-BDE10CDD830BQ33381190-F45BD7EC-C44C-4146-B171-3BD944505A1FQ33763815-D5952D5D-252E-4D57-B10D-696079A1022EQ34026320-C5E94A1E-7A0F-4A5E-9A5E-26D3B4D9DE9CQ35057674-0D7A1CF9-6EC8-467C-9EF0-525BA66EB62CQ35119305-5253F646-7342-43A8-9E8E-B21BA58A01BBQ36080941-6A7E2AA6-11F8-43AF-BAB9-B1A893A8B316Q36401755-6159B4C9-73B9-4D83-A53D-0F6E2C14AECEQ36414165-EE25C982-214A-4F16-8CF6-42FEAFF29C5BQ37886763-57746ACA-DB03-4A0B-936F-E25744829662Q38051849-6D00E370-89BF-43AE-BDBD-56E0F455C907Q38185361-ECDD1661-6CFE-4D68-AFA3-0F284054A9F2Q38696605-737D147D-6B78-4279-B927-FFF542391BF8Q38755419-AB6F59FB-3461-41D7-975F-B2EEBF45D639Q38779048-16C8BFDC-A205-4BA6-B40E-8F390296D917Q39206370-C85827CA-FAE5-45D4-8AD0-50BEC9467F32Q39850743-1BC62219-5C7E-40DB-9374-18DA7B2FEB5CQ39884096-FC328D7B-B8DA-47B6-977E-BD66B3C60AE3Q40508973-E5848669-4CDD-40C3-858C-65895FB92969Q40536758-1B859B27-7BC3-46D0-88DE-1B643D958D8CQ40721398-3D953FDD-A1CE-4AF1-8E30-4BE40B0EAE86Q40756547-FB7F498D-39F8-4A73-874B-5275749ABF3AQ40771069-49D54E57-4CCE-4442-838B-814B6F2ABE15Q40958639-DD8D4306-21F0-409A-A1A2-6DED3A0E49FDQ41050745-36C10138-5FE7-413C-AD58-AB8C33113BDCQ41113160-2F977440-03FA-4F95-81F1-05E9C48E332BQ41341129-2AE03F12-96CA-40B6-A3E4-5B13FDE3A98DQ41349846-5C88D59B-997A-41BE-9617-A9868B99960AQ41362156-4E2C8DDC-6BBC-4460-8654-F7A97687B698Q41536355-0F7ED746-1009-412F-A3FD-A68DB649ACFEQ41651309-0B46374A-4361-4BDE-96ED-6D1A0A0180FEQ41653704-DA3DBE4F-604B-4C8D-9FD2-74BA18EC673CQ41719249-91873E47-D9DB-42ED-8580-E14D3EB99434Q41766759-881833A2-25F1-4011-AE89-4900D71C1557Q41858266-65DBAA59-2524-4ED6-A129-CDF8A7E55532Q41994799-A34D22BF-1F09-4CB0-8DB0-7327610DDE1AQ42465369-629EEC65-69CC-4559-B426-1871E47FF74DQ42467713-1FC4DAF8-FA78-4774-B526-20912AA067FA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sandip M Kanse
@nl
Sandip M Kanse
@sl
Sandip M. Kanse
@en
Sandip M. Kanse
@es
type
label
Sandip M Kanse
@nl
Sandip M Kanse
@sl
Sandip M. Kanse
@en
Sandip M. Kanse
@es
altLabel
Sandip Kanse
@en
Sandip M. Kanse
@en
prefLabel
Sandip M Kanse
@nl
Sandip M Kanse
@sl
Sandip M. Kanse
@en
Sandip M. Kanse
@es
P108
P106
P1153
7003938808
P31
P496
0000-0003-0782-9957